This article is more than 5 years old. Information may no longer be current.
Welcome to the Premier Issue of Cell Therapy Next
Click Here to Manage Email Alerts
With the approval of two chimeric antigen receptor T-cell therapies in the past year, the need arose for quality information and education about these new and promising treatments in the hematologic oncology community. This new, timely publication from the editors and publishers of HemOnc Today, your trusted news source in hematology and oncology, looks to deliver on that need.
Cell Therapy Next sets out to review the paths to these approvals and how these cutting-edge treatments are being put into practice. Experts will contribute insight on patient selection, financial impact and insurance coverage, the latest data presented at national meetings and more. In-depth profiles of leading cancer centers at the forefront of research and treatment will give a glimpse into the current and future of cell therapies.
“There’s certainly more to come. By studying the limitations, by pushing the envelopes, we are learning where we need to make the tweaks or the major changes that will take us to the next level and more difficult to treat diseases,” Saar I. Gill, MD, PhD, told Cell Therapy Next for our first feature on the University of Pennsylvania (find the story here). “I love seeing the fact that other centers achieve the same results we do. This means that our results are not a flash in the pan. It means they are reproducible. It means that they are real. ... That’s what matters the most to a scientist, to a physician. This is not a one-hit wonder. While competition is certainly a good thing, we are more similar than we are different. That’s actually a really good thing.”
This publication will follow the CAR T evolution from late-line treatment to early-line treatment, and from its current narrow scale of highly selected clinical trials and cancer types to a broader set of approvals and applications. Cell therapies are poised to be the next frontier in hematologic and oncologic patient care and Cell Therapy Next plans to be there for the move forward.
In this premier issue, you can learn about the sole guidelines that exist in CAR T-cell therapy (find the story here) as well as dive into patient selection (find the story here) with our Peer Perspective Board member, Ryan D. Cassaday, MD.
“Understanding those basic, practical, logistical issues in advance will help do a better job of understanding which patients to whom we can genuinely and honestly recommend this therapy,” he told Cell Therapy Next.
Cell Therapy Next launched at the American Society for Hematology annual meeting in December. Look for us to delve further into these issues throughout 2019. To give us your input, participate in future features or suggest questions for us to answer, please email us at CellTherapyNext@Healio.com.
The Editors and Publishers of Cell Therapy Next